Literature DB >> 8309002

Localization of endothelin receptors in the human prostate.

S Kobayashi1, R Tang, B Wang, T Opgenorth, E Stein, E Shapiro, H Lepor.   

Abstract

The objective of the present study was to localize endothelin receptors in the human prostate using quantitative autoradiography. Slide-mounted tissue sections 20 microns. in thickness were obtained from the transition zones of seven patients undergoing radical prostatectomies for low volume prostate cancer. Sarafotoxin (S6C) and BQ123 have been used to distinguish endothelin receptor subtypes (ETA and ETB). The prostatic tissue sections were incubated in four different stock solutions containing the following: 0.1 nM. 125I-endothelin-1 (125I-ET-1) (total ET-1 binding); 0.1 nM. 125I-ET-1 and 100 nM. S6C (total ETA binding); 0.1 nM. 125I-ET-1 and 1 microM. BQ123 (total ETB binding); and 0.1 nM. 125I-ET-1 and 1 microM. ET-1 (nonspecific ET-1 binding). Nonspecific binding accounted for only 12 and 15% of total 125I-ET-1 binding in the stroma and glandular epithelium. Autoradiograms were quantitatively analyzed using a computerized image analysis system. Specific radioactive densities (nCi/mg.) were determined for the stromal and glandular epithelial elements of the prostate. The specific radioactive densities of ETA and ETB binding sites in the stroma were 7.57 +/- 0.65 and 2.98 +/- 0.81. The specific radioactive densities of ETA and ETB binding sites in the glandular epithelium were 1.59 +/- 0.15 and 7.87 +/- 1.35. The present study demonstrates that the predominant endothelin receptors in the stroma and glandular epithelium are the ETA and ETB subtypes, respectively.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8309002     DOI: 10.1016/s0022-5347(17)35083-8

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  10 in total

1.  Pharmacological characterization of endothelin receptor subtypes in the guinea-pig prostate gland.

Authors:  W A Lau; S L Cox; J N Pennefather; F J Mitchelson
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

2.  Big endothelin-1 but not endothelin-1 is present in the smooth muscle stroma of the prostate gland of the rat.

Authors:  S Ventura; A Salamoussa
Journal:  J Anat       Date:  2002-02       Impact factor: 2.610

Review 3.  Endothelin receptor antagonists.

Authors:  Joel B Nelson
Journal:  World J Urol       Date:  2005-01-15       Impact factor: 4.226

4.  Endothelin receptor A blockade enhances taxane effects in prostate cancer.

Authors:  Ardavan Akhavan; Kevin H McHugh; Georgi Guruli; Robert R Bies; William C Zamboni; Sandra A Strychor; Joel B Nelson; Beth R Pflug
Journal:  Neoplasia       Date:  2006-09       Impact factor: 5.715

5.  Expression of endothelin receptor subtypes and their messenger RNAs in diabetic rat prostate: effect of insulin treatment.

Authors:  M Saito; Y Wada; K Ikeda; Z Wang; H E Foster; S D Smith; R M Weiss; J Latifpour
Journal:  Mol Cell Biochem       Date:  2000-07       Impact factor: 3.396

Review 6.  Is Tamsulosin Linked to Dementia in the Elderly?

Authors:  Jason K Frankel; Yinghui Duan; Peter C Albertsen
Journal:  Curr Urol Rep       Date:  2018-07-03       Impact factor: 3.092

7.  A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer.

Authors:  William R Schelman; Glenn Liu; George Wilding; Thomas Morris; De Phung; Robert Dreicer
Journal:  Invest New Drugs       Date:  2009-09-19       Impact factor: 3.850

8.  Endothelin-1 enhances the expression of the androgen receptor via activation of the c-myc pathway in prostate cancer cells.

Authors:  June G Lee; Rong Zheng; Jennifer M McCafferty-Cepero; Kerry L Burnstein; David M Nanus; Ruoqian Shen
Journal:  Mol Carcinog       Date:  2009-02       Impact factor: 4.784

Review 9.  Endothelin-1 as a target for therapeutic intervention in prostate cancer.

Authors:  E Scott Kopetz; Joel B Nelson; Michael A Carducci
Journal:  Invest New Drugs       Date:  2002-05       Impact factor: 3.850

10.  Atrasentan in Patients With Advanced Renal Cell Carcinoma: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E6800).

Authors:  Michael A Carducci; Judith Manola; Suresh G Nair; Glenn Liu; Steven Rousey; Janice P Dutcher; George Wilding
Journal:  Clin Genitourin Cancer       Date:  2015-07-17       Impact factor: 2.872

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.